I'm puzzled by the title of the first abstract, specifically why it mentions CVD but not improved kidney function.

I'd been wondering if it's because the embargo prevents authors from including in the title any reference to the nature of any new results to be presented (given that the CVD data have been public since the AHA). So I looked at the titles of the late-breaking abstracts of the 2019 meeting, and found that at least two of them did refer to the direction of new results, presumably meaning it is permitted.

So if kidney function was improved (eGFR increased), and the authors were allowed to say so in the title, why did they not do so?